Limits...
Combination of circulating tumor cells with serum carcinoembryonic antigen enhances clinical prediction of non-small cell lung cancer.

Chen X, Wang X, He H, Liu Z, Hu JF, Li W - PLoS ONE (2015)

Bottom Line: We aimed to seek clinical variables that enhance the prediction of CTCs in patients with non-small cell lung cancer (NSCLC).However, the level of CTCs was not associated with the degree of nodal involvement (N) or tumor prognostic markers Ki-67, CA125, CA199, Cyfra21-1, and SCCA.Using logistic regression analysis, we found that the combination of CTCs with tumor marker CEA has a better disease prediction.

View Article: PubMed Central - PubMed

Affiliation: Cancer and Stem Cell Center, First Affiliated Hospital, Jilin University, Changchun, Jilin 130061, P.R. China.

ABSTRACT
Circulating tumor cells (CTCs) have emerged as a potential biomarker in the diagnosis, prognosis, treatment, and surveillance of lung cancer. However, CTC detection is not only costly, but its sensitivity is also low, thus limiting its usage and the collection of robust data regarding the significance of CTCs in lung cancer. We aimed to seek clinical variables that enhance the prediction of CTCs in patients with non-small cell lung cancer (NSCLC). Clinical samples and pathological data were collected from 169 NSCLC patients. CTCs were detected by CellSearch and tumor markers were detected using the Luminex xMAP assay. Univariate analyses revealed that histology, tumor stage, tumor size, invasiveness, tumor grade and carcinoembryonic antigen (CEA) were associated with the presence of CTCs. However, the level of CTCs was not associated with the degree of nodal involvement (N) or tumor prognostic markers Ki-67, CA125, CA199, Cyfra21-1, and SCCA. Using logistic regression analysis, we found that the combination of CTCs with tumor marker CEA has a better disease prediction. Advanced stage NSCLC patients with elevated CEA had higher numbers of CTCs. These data suggest a useful prediction model by combining CTCs with serum CEA in NSCLC patients.

No MeSH data available.


Related in: MedlinePlus

Immunostaining of a single lung cancer CTC isolated from patient peripheral blood.Positive immunomagnetic selection with anti-EpCAM Ab was followed by morphological confirmation with staining for cytokeratins (cytoplasm), DAPI (nucleus), and CD45 (negative).
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4440620&req=5

pone.0126276.g001: Immunostaining of a single lung cancer CTC isolated from patient peripheral blood.Positive immunomagnetic selection with anti-EpCAM Ab was followed by morphological confirmation with staining for cytokeratins (cytoplasm), DAPI (nucleus), and CD45 (negative).

Mentions: One hundred and sixty-nine patients with NSCLC were recruited between July 2012 and January 2014, and their characteristics were recorded (Table 1). CTCs were quantified from a 7.5 mL blood sample for each patient (Fig 1). The median follow-up duration was 1.1 years. Thus, survival analysis would not be conducted on this cohort population. Overall, the prediction of NSCLC by CTCs was relatively low in our cohort samples. In a total of 169 NSCLC patients, only 40 (23.7%) patients exhibited positive CTC detection (>1 per 7.5 mL blood), in a similar agreement with that reported in western populations [15, 21–22].


Combination of circulating tumor cells with serum carcinoembryonic antigen enhances clinical prediction of non-small cell lung cancer.

Chen X, Wang X, He H, Liu Z, Hu JF, Li W - PLoS ONE (2015)

Immunostaining of a single lung cancer CTC isolated from patient peripheral blood.Positive immunomagnetic selection with anti-EpCAM Ab was followed by morphological confirmation with staining for cytokeratins (cytoplasm), DAPI (nucleus), and CD45 (negative).
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4440620&req=5

pone.0126276.g001: Immunostaining of a single lung cancer CTC isolated from patient peripheral blood.Positive immunomagnetic selection with anti-EpCAM Ab was followed by morphological confirmation with staining for cytokeratins (cytoplasm), DAPI (nucleus), and CD45 (negative).
Mentions: One hundred and sixty-nine patients with NSCLC were recruited between July 2012 and January 2014, and their characteristics were recorded (Table 1). CTCs were quantified from a 7.5 mL blood sample for each patient (Fig 1). The median follow-up duration was 1.1 years. Thus, survival analysis would not be conducted on this cohort population. Overall, the prediction of NSCLC by CTCs was relatively low in our cohort samples. In a total of 169 NSCLC patients, only 40 (23.7%) patients exhibited positive CTC detection (>1 per 7.5 mL blood), in a similar agreement with that reported in western populations [15, 21–22].

Bottom Line: We aimed to seek clinical variables that enhance the prediction of CTCs in patients with non-small cell lung cancer (NSCLC).However, the level of CTCs was not associated with the degree of nodal involvement (N) or tumor prognostic markers Ki-67, CA125, CA199, Cyfra21-1, and SCCA.Using logistic regression analysis, we found that the combination of CTCs with tumor marker CEA has a better disease prediction.

View Article: PubMed Central - PubMed

Affiliation: Cancer and Stem Cell Center, First Affiliated Hospital, Jilin University, Changchun, Jilin 130061, P.R. China.

ABSTRACT
Circulating tumor cells (CTCs) have emerged as a potential biomarker in the diagnosis, prognosis, treatment, and surveillance of lung cancer. However, CTC detection is not only costly, but its sensitivity is also low, thus limiting its usage and the collection of robust data regarding the significance of CTCs in lung cancer. We aimed to seek clinical variables that enhance the prediction of CTCs in patients with non-small cell lung cancer (NSCLC). Clinical samples and pathological data were collected from 169 NSCLC patients. CTCs were detected by CellSearch and tumor markers were detected using the Luminex xMAP assay. Univariate analyses revealed that histology, tumor stage, tumor size, invasiveness, tumor grade and carcinoembryonic antigen (CEA) were associated with the presence of CTCs. However, the level of CTCs was not associated with the degree of nodal involvement (N) or tumor prognostic markers Ki-67, CA125, CA199, Cyfra21-1, and SCCA. Using logistic regression analysis, we found that the combination of CTCs with tumor marker CEA has a better disease prediction. Advanced stage NSCLC patients with elevated CEA had higher numbers of CTCs. These data suggest a useful prediction model by combining CTCs with serum CEA in NSCLC patients.

No MeSH data available.


Related in: MedlinePlus